# Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors

> **NCT03692520** · PHASE1 · UNKNOWN · sponsor: **Sinocelltech Ltd.** · enrollment: 90 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **BIOLOGICAL:** SCT200

## Key facts

- **NCT ID:** NCT03692520
- **Lead sponsor:** Sinocelltech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-30
- **Primary completion:** 2019-11-30
- **Final completion:** 2020-04-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2018-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03692520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03692520, "Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03692520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*